FNAM Stock Overview
Engages in the research and identification of positively selected genes in humans, animals, and commercial crops.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Evolutionary Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0008 |
| 52 Week High | US$0.0008 |
| 52 Week Low | US$0.0008 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.91% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| FNAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -1.9% |
| 1Y | n/a | 20.2% | 30.4% |
Return vs Industry: Insufficient data to determine how FNAM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FNAM performed against the US Market.
Price Volatility
| FNAM volatility | |
|---|---|
| FNAM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: FNAM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine FNAM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Steve Warnecke | www.evolgen.com |
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities.
Evolutionary Genomics, Inc. Fundamentals Summary
| FNAM fundamental statistics | |
|---|---|
| Market cap | US$5.32k |
| Earnings (TTM) | -US$2.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FNAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNAM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.25m |
| Earnings | -US$2.25m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did FNAM perform over the long term?
See historical performance and comparison